Search bioRxivSearch

Biology subjects

Goldschmidt, Y.

Publications and source records attributed to Goldschmidt, Y..

2 recordsLinked to original sources

Characterizing Subpopulations with Better Response to Treatment Using Observational Data - an Epilepsy Case Study

Electronic health records and health insurance claims, providing observational data on millions of patients, offer great opportunities, and challenges, for population health studies. The objective of this study is identifying subpopulations that are likely to benefit from a given treatment using observational data. We refer to these subpopulations as \"better responders\" and focus on characterizing these using linear scores with a limited number of variables. Building upon well-established causal inference techniques for analyzing observational data, we propose two algorithms that generate such scores for identifying better responders, as well as methods for evaluating and comparing these scores. We applied our methodology to a large dataset of ~135,000 epilepsy patients derived from claims data. Out of this sample, 85,000 were used to characterize subpopulations with better response to next-generation (\"Newer\") anti-epileptic drugs (AEDs), compared to an alternative treatment by first-generation (\"Older\") AEDs. The remaining 50,000 epilepsy patients were then used to evaluate our scores. Our results demonstrate the ability of our scores to identify large subpopulations of epilepsy patients with significantly better response to newer AEDs.

epidemiology

Estimating Effects Of Second Line Therapy For Type 2 Diabetes Mellitus: Retrospective Cohort Study

ObjectiveMetformin is the recommended initial drug treatment in type 2 Diabetes Mellitus, but there is no clearly preferred choice for an additional drug when indicated. We use electronic health records to infer the counterfactual drug effectiveness in reducing HbA1c levels and effect on body-mass index (BMI) of four second line diabetes drug classes.\n\nStudy design and settingRetrospective analysis of the electronic health records of US-based patients in the Explorys database using causal inference methodology to adjust for censored patients and confounders.\n\nParticipants and ExposuresOur cohort consisted of roughly 25,000 patients with type 2 diabetes, prescribed metformin along with a drug out of four second line drug classes - sulfonylureas, thiazolidinediones, DPP-4 inhibitors and GLP-1 agonists, during the years 2000-2013.\n\nMain outcome measuresGlycated hemoglobin (HbA1c) and BMI of these patients after six and twelve months of treatment.\n\nResultsWe show that all four drug classes reduce glycated hemoglobin levels, but the effect of sulfonylureas after 12 months of treatment is less pronounced compared to other classes. We also predict that thiazolidinediones increase body weight while DPP-4 inhibitors decrease it.\n\nConclusionOur results are in line with current knowledge on second line drug effectiveness and effect on BMI. They demonstrate that causal inference from Electronic health records is an effective way for conducting multi-treatment causal inference studies.

epidemiology